HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Rovin BH, Houssiau F, Furie R, et al.

Belimumab (BEL) Improves Renal Outcomes in Active Lupus Nephritis (LN): A Phase 3 Randomized, Placebo (PBO)-Controlled Trial

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:54A 2020

BACKGROUND

BEL is approved for patients (pts) with systemic lupus erythematosus (SLE). We evaluated intravenous (IV) BEL in active LN.

METHODS

This 104-week trial (GSK Study BEL114054; NCT01639339) randomized adults with active LN (class III, IV, and/or V) 1:1 to monthly BEL 10 mg/kg IV or PBO, plus standard therapy (ST) with high-dose corticosteroids + either cyclophosphamide (CyC) or mycophenolate mofetil (MMF) for induction at the investigator’s discretion. CyC was followed by azathioprine (AZA), and MMF by MMF maintenance. The primary endpoint was Primary Efficacy Renal Response (PERR = urine protein:creatinine ratio [uPCR] ≤0.7; estimated glomerular filtration rate [eGFR] no more than 20% below pre-flare value or ≥60 ml/min/1.73m2; no rescue therapy) at Week 104. Other endpoints were Complete Renal Response (CRR = uPCR <0.5; eGFR no more than 10% below pre-flare value or ≥90 ml/min/1.73m2; no rescue therapy) at Week 104; time to renal event (end-stage kidney disease, doubling of serum creatinine, increased proteinuria and/or impaired renal function, renal disease-related treatment failure) or death. Endpoints were analyzed by ST regimen.

RESULTS

224 pts were randomized to each arm. At Week 104, there were significantly more PERR and CRR responders on BEL vs PBO: (43.0% vs 32.3%, OR [95% CI] 1.6 [1.0, 2.3]; p=0.03) and (30.0% vs 19.7%, OR [95% CI] 1.7 [1.1, 2.7]; p=0.02), respectively. Risk of renal event or death was lower in BEL pts relative to PBO (HR [95% CI] 0.5 [0.3, 0.8]; p<0.01). Week 104 PERR response rates in pts on CyC/AZA were 33.9% with BEL and 27.1% with PBO, and 46.3% with BEL vs 34.1% with PBO in those on MMF. BEL reduced risk of renal event or death on background of CYC/AZA (HR [95% CI] 0.5 [0.2, 1.0]) and MMF (HR [95% CI] 0.5 [0.3, 0.8]) relative to PBO. Adverse events (AEs; ≥1) occurred in 95.5% of BEL and 94.2% of PBO pts, and 25.9% of BEL and 29.9% of PBO pts had ≥1 serious AE.

CONCLUSION

The addition of BEL to commonly used ST for the treatment of LN significantly improved renal responses with no unexpected safety signals.

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.